Introduction 40
With the increasing use of whole-exome sequencing (WES) and whole-genome sequencing 41 (WGS) to diagnose patients with a suspected genetic disorder, diagnostic yield is steadily 42 One strategy to manage the list of genetic variants is to perform trio analysis of samples 51 from the proband and both of his or her biological parents to ascertain, for instance, 52
whether a variant has de novo status 4 . Another strategy is to limit the analyses to a gene 53 panel of Online Mendelian Inheritance in Men (OMIM) disease-annotated genes 5 . However, most available algorithms are based on existing knowledge on human 75 disease genes, their orthologues in animal models, or well-described biological pathways 76 (for a detailed review see 11 ). 77
To overcome this, we hypothesized that co-regulation of expression data could be used to 78 prioritize variants, including those in less well studied genes. We assumed that if a gene or 79 a gene set is known to cause a specific disease or disease symptom, these genes will often 80 have similar molecular functions or be involved in the same biological process or pathway. 81 We reasoned that variants in genes with yet unknown function that are involved in the same 82 biological pathway or co-regulated with known disease genes likely result in the same 83 phenotype. In order to identify groups of genes with a related biological function, we used 84 an expansive compendium of 31,499 RNA-sequencing (RNA-seq) gene expression samples 85 to predict functions for genes with high accuracy. 86 We then developed a user-friendly tool that can prioritize variants in known and unknown 87 genes based on our functional predictions, which we designated GeneNetwork Assisted 88 Diagnostic Optimization (GADO). GADO ranks variants based on gene co-regulation in 89 publicly available expression data of a wide range of tissues and cell types using HPO terms 90 to describe a patient's phenotype. To validate our prioritization method, we tested how well 91 our method predicts disease-causing genes based on features described for each of the 92 genes in the OMIM database. We then used exome sequencing data of patients with a 93 known genetic diagnosis to benchmark GADO. Finally, we applied our methodology to 94 previously inconclusive WES data and identified several genes that contain variants that 95 likely explain the phenotype of the respective patients. Thus, we show that our methodology 96 is successful in identifying variants in novel, potentially relevant genes explaining the 97 patient's phenotype. 98 Although these samples are generated in many different laboratories, we previously 134 observed that, after having corrected for technical biases, it is possible to integrate these 135 samples into a single expression dataset 18 . We validated that this is also true for our new 136 dataset by visualizing the data using t-Distributed Stochastic Neighbor Embedding (t-SNE). 137
We labeled the samples based on cell-type or tissue and we observed that samples cluster 138 together based on cell-type or tissue origin (Figure 2a) . Technical biases, such as whether 139 single-end or paired-end sequencing had been used, did not lead to erroneous clusters, 140 which suggests that this heterogeneous dataset can be used to ascertain co-regulation 141 between genes and can thus serve as the basis for predicting the functions of genes. 142
Prediction of gene HPO associations and gene functions 143
To predict HPO term associations and putative gene functions using co-regulation ( Figure  144 1b), we used a method that we had previously developed and applied to public expression 145 microarrays 19 . Since these microarrays only cover a subset of the protein-coding genes (n 146 = 14,510), we decided to use public RNA-seq data instead. This allows for more accurate 147 quantification of lower expressed genes and the expression quantification of many more 148 genes, including a large number of non-protein-coding genes.
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We applied this prediction methodology 19 to the HPO gene sets and also to Reactome 
164
Prioritization of known disease genes using the annotated HPO terms 165
Once we had calculated the prediction scores of HPO disease phenotypes, we leveraged 166 these scores to prioritize genes found by sequencing the DNA of a patient. For each 167
individual HPO term-gene combination, we calculated a prediction z-score that can be used 168 to rank genes. In practice, however, patients often present with not one feature but a 169 combination of multiple features. Therefore, we combined the z-scores for each HPO term 24 
170
to generate an overall z-score that explains the full spectrum of features in a patient. GADO 171 uses these combined z-scores to prioritize the candidate genes: the higher the combined z-172 score for a gene, the more likely it explains the patient's phenotype. 173
Because many HPO terms have fewer than 10 genes annotated, and since we were unable 174 to make significant predictions for some HPO terms, certain HPO terms are not suitable to 175 use for gene prioritization. We solved this problem by taking advantage of the way HPO 176 terms are structured. Each term has at least one parent HPO term that describes a more 177 generic phenotype and thus has also more genes assigned to it. Therefore, if an HPO term 178 cannot be used, GADO will make suggestions for suitable parental terms (supplementary 179 figure 1 ). 180
To benchmark our prioritization method, we used the OMIM database 5 . We tested how well 181 our method was able to retrospectively rank disease-causing genes listed in OMIM based on 182 the annotated symptoms of these diseases. We took each OMIM disease gene (n = 3,382) 183 and used the associated disease features (15 per gene on average) as input for GADO. 184
What we found was that for 49% of the diseases GADO ranks the causative gene in the top 185 5% (Figure 3a, b) . Moreover, we observed a statistically significant difference between the 186 performance of GADO on true gene-phenotype combinations and its performance using a 187 random permutation of gene-phenotype combinations (p-value = 2.16 × 10 however, be due to very low expression levels of SLC6A3 in most tissues except specific 205 brain regions 28 . 206
To better understand why we can't predict HPO terms for all genes, we used the Reactome, 207 GO and KEGG prediction scores. Jointly these databases comprise thousands of gene sets. 208
Since these databases describe such a wide range of biology, we assumed that if a gene 209 does not show any prediction signal for any gene set in these databases, gene co-210 expression is probably not informative for this gene. To quantify this, we calculated, per 211 gene, the average skewness of the z-score distribution of the Reactome, GO and KEGG gene 212 sets. From this we were able to derive a 'gene predictability score' for every gene that is 213 independent of whether this gene is already known to play a role in any a disease or 214 pathway (Figure 3c , d, e). We then ascertained whether these 'gene predictability scores' 215 are correlated with the prediction z-score of the OMIM diseases, and found a strong 216 correlation (Pearson r = 0.54, p-value = 1.14 × 10 -332 ) between the gene predictability 217 scores and GADO's ability to identify a known disease gene (Figure 3c) . 218
To investigate why some genes have a high 'gene predictability score' but low prediction 219 performance, we scored a set of genes known to cause cardiomyopathy (CM) for the 220 amount of literature evidence that these genes cause CM. We found several genes for which 221 the prediction score for the CM phenotype is lower than expected based on the gene 222 However, this gene is primarily expressed in the liver. Therefore, its disease mechanism is 226 different from other mechanisms resulting in CM, as many inherited CMs are caused by 227 deleterious variants in genes highly expressed in the heart and directly affecting the 228 function of the cardiac sarcomere. Therefore, the phenotypic function prediction for this 229 gene may be worse than we would expect based on the predictability score. We performed a 230 similar analysis using the HPO term 'dilated cardiomyopathy' and observed a low prediction 231 performance for the TMPO gene, despite a high gene predictability score (supplementary 232 figure 2b). Previously, this gene was reported to be related to dilated cardiomyopathy 233 (DCM) and listed as such by OMIM. However, recent reclassification of the reported variants 234 using the ExAC data revealed that the reported variant was far too common to be causative 235 for DCM 30 . 236
Benchmarking GADO using solved cases with realistic phenotyping 237
Although in silico benchmarking demonstrated the potential of GADO, it used all annotated 238 HPO terms for a disease. In practice, however, patients may only present with a limited 239 number of the annotated features. To perform a validation that was a more realistic 240 reflection of clinical practice, we used exome sequencing data of 83 patients with a known 241 genetic diagnosis. We used their phenotypic features as listed in their medical records prior 242 to the genetic diagnosis (supplementary table 2). On average, per patient, GADO yielded 56 243 possible disease-causing genes with variants that are rare and predicted to be deleterious. 244
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In 41% of the patients the actual causative gene was ranked in the top 3 and in 50% of the 245 cases it was in the top 5 (mean rank 10) (Figure 4a) . 246
Clustering of HPO terms 247
In addition to ranking potentially causative genes based on a patient's phenotype, we 248 observed that GADO can be used to cluster HPO terms based on the genes that are predicted 249 to be associated to these HPO terms. This can help identify pairs of symptoms that often occur 250 together, as well as symptoms that rarely co-occur, and we actually observed this for a patient 251 
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Reanalysis of previously unsolved cases 266
To assess GADO's ability to discover new disease genes, we applied it to data from 38 267 patients who are suspected to have a Mendelian disease but who have not had a genetic 268 diagnosis. All patients had undergone prior genetic testing (WES with analysis of a gene 269 panel according to their phenotype, supplementary table 3). On average three genes had a 270 z-score ≥ 5 (which we used as an arbitrary cut-off and that correspond to a p-value of 5.7 X 271 10 -7
) and were further assessed. In seven cases, we identified variants in genes not 272 associated to a disease in OMIM or other databases, but for which we could find literature or 273 for which we gained functional evidence implicating their disease relevance ( All analyses described in this paper can be performed using our online toolbox at 288 www.genenetwork.nl. Users can perform gene prioritizations using GADO by providing a set 289 of HPO terms and a list of candidate genes (Figure 5a) . Per gene, it is also possible to 290 download all prediction scores for the HPO terms and pathways. Our co-regulation scores 291 between genes can be used for clustering. Furthermore, the predicted pathway and HPO 292 14 annotations of genes can be used to perform function enrichment analysis (Figure 5b) Importantly, GADO can also aid in the discovery of currently unknown disease genes. The 313 main advantage of our methodology is that it does not rely on any prior knowledge about 314 disease-gene annotations. Instead, we used predicted gene functions based on co-315 expression networks extracted from a large compendium of publicly available RNA-seq 316 samples. RNA-seq has previously shown to be very helpful to accurately quantify expression 317 levels of lowly expressed genes and non-coding genes 18 . To evaluate our diagnostic 318 algorithm, we developed a testing scenario based on simulated patients presenting with all 319 clinical features listed in OMIM for a certain disease or syndrome. This validation test 320
showed that for 49% of the diseases the causative gene ranks in the top 5%. We also 321 investigated the OMIM "provisional" category of genes for which there is limited evidence. 322
Both the OMIM disease-gene annotation and the provisional annotations perform 323 significantly better than a random permutation. While we do find a small but significant 324 difference in prediction performance between the provisionally annotated genes and the 325 more established disease associated genes, we conclude, based on our findings, that these 326 provisional OMIM annotations are generally of similar reliability to the other OMIM disease 327
annotations. 328
Benchmarking on sequence data of patients with a known genetic diagnosis revealed that 329 GADO returned the real causative variant within the top 3 results for 41% of the samples, 330
indicating the potential power of GADO for a large number of diseases. Finally, in seven 331 patients, GADO was able to identify potential novel disease genes that are strong candidates 332 based on literature or functional evidence. For other cases we have identified genes with a 333 strong prediction score harboring variants that might explain the phenotype. However, since 334 very little is known about these genes it is not yet possible to draw firm conclusions. 335
Hopefully this will become possible in the near future through initiatives like Genematcher 336 40 . 337
Potential to discover novel human disease genes 338
Over the last decade, several computational tools have been developed to prioritize variants 339 in genes. Some, such as GAVIN, focus on variant filtering and prioritization based on 340 deleteriousness scores, allele frequency and inheritance model currently annotated in any of the databases we used, and there are even more non-coding 354 genes for which the biological function or role in disease is unknown. Since GADO does not 355 rely on prior knowledge, it can be used to prioritize variants in both coding and non-coding 356 genes (for which no or limited information is available). GADO thus enables the discovery of 357 novel human disease genes and can complement existing tools in analyzing the genomic 358 data of patients who have a broad spectrum of phenotypic abnormalities. 359
Limitations 360
The gene predictability score indicates for which genes we can reliably predict phenotypic 361 associations and for which genes we cannot based on gene co-regulation. This score gives 362 insight into which genes are expected to perform poorly in our prioritization. We found 363 strong correlation between these gene predictability scores and the gene prioritization z-364 scores. Thus, genes with a high predictability score have more accurate HPO term 365 predictions. However, since our predictions primarily rely on co-activation patterns that we 366 identified from RNA-seq data, our method does not perform well for genes where gene-367 expression patterns are not informative of their function. This could, for instance, be the 368 18 case for proteins relying heavily on post-translation modifications for regulation or genes for 369 which different transcripts have distinct functions. This last limitation can potentially be 370 overcome by predicting HPO-isoform associations by using transcript-based expression 371 quantification. 372
Insufficient statistical power to obtain accurate predictions may be another explanation for 373 the low predictability scores of certain genes. This may be true for genes that are poorly 374 expressed or expressed in only a few of the available RNA-seq samples. The latter issue we 375 expect to overcome in the near future as the availability of RNA-seq data in public 376 repositories is rapidly increasing. Initiatives such as Recount enable easy analysis on these 377 samples 42 , allowing us to update our predictions in the future, thereby increasing our 378 prediction accuracy. 379
For some genes we are unable to predict annotated disease associations despite having a 380 high gene predictability scores. Some genes, such as TTR, simply act in a manner unique to 381 a specific phenotype. Other genes, such as TMPO, turned out to be false positive disease 382 associations. These examples show that our gene predictability score has the potential to 383 flag genes acting in a unique manner as well as genes that might be incorrectly assigned to 384 a certain disease or phenotype. 385
We noted that the median prediction performance of HPO terms is lower compared to the 386 other gene sets databases used in our study, such as Reactome. This may be due to the 387 fact that phenotypes can arise by disrupting multiple distinct biological pathways. For 388 instance, DCMs can be caused by variants in sarcomeric protein genes, but also by variants 389 in calcium/sodium handling genes or by transcription factor genes 43 . As our methodology 390 makes guilt-by-association predictions based on whether genes are showing similar 391 expression levels, the fact that multiple separately working processes are related to the 392 same phenotype can reduce the accuracy of the predictions (although it is often still 393 possible to use these predictions as the DCM HPO phenotype prediction performance AUC = 394
0.76). 395
Complexity 396
Given that nearly 5% of patients with a Mendelian disease have another genetic disease 44 , 397
it is important to consider that multiple genes might each contribute to specific phenotypic 398 effects. Clinically, it can be difficult to assess if a patient suffers from two inherited 399 conditions, which may hinder variant interpretation based on HPO terms. We showed that 400 GADO can disentangle the phenotypic features of two different diseases manifesting in one 401 patient by correlating and subsequently clustering the profiles of HPO terms describing the 402 patient's phenotype. If the HPO terms observed for a patient do not correlate, it is more 403 likely that they are caused by two different diseases. An early indication that this might be 404 the case for a specific patient can simplify subsequent analysis because the geneticist or 405 laboratory specialist performing the variant interpretation can take this in consideration. 406 GADO also facilitates separate prioritizations on subsets of the phenotypic features. 407
Conclusion 408
Connecting variants to disease is a complex multistep process. The early steps are usually 409 highly automated, but the final most critical interpretations still rely on expert review and 410 human interpretation. GADO is a novel approach that can aid users in prioritizing genes 411 using patient-specific HPO terms, thereby speeding-up the diagnostic process. setting, in addition to all default settings, was used: -k 31. 444
The following Kallisto settings were used mapping all 67,019 samples using default settings 445 for paired-end data mapping. For single-end data mapping we used the following settings in 446 addition to the defaults: -l 200 and -s 20 -bias. 447
After obtaining the transcript counts per sample, these transcript-level counts were summed 448 to gene-level counts for each sample. 449
450
Gene quality control 451
We quantified 66,233 genes, which were filtered on the criteria described below, after which 452 56,435 genes remained. Twenty-nine gene names were duplicates/identical. After these 453 were removed, 66,203 genes remained. Of these, 3,628 genes are not expressed (0 reads 454 detected among 31,499 samples) and were removed, leaving 62,575 genes. Next, we 455 detected a number of duplicate genes (100% sequence similarity). Since these genes with 456 perfect sequence similarity have exactly the same number of reads mapping, we were 457 concerned they would appear as perfectly co-expressed genes in our analysis. Most of these 458 genes are either incorrectly mapped genes in the genome build or duplicates of their 459 biological counterpart. Due to their high sequence similarity they are indistinguishable to the 460 mapping tool (potentially introducing false correlations). To avoid potential biases resulting 461 in deceptively high co-expression values, we decided to remove this bias prior to our 462 analysis. 5,471 of these were not located on chromosomes (but on scaffolds), and were 463 removed, leaving 57,104 genes. Another 665 genes had identical transcripts: different IDs, 464 but 100% identical sequences (e.g. ENST00000442165 and ENST00000446969). 465
An additional four genes had no expression in any of the remaining samples after removing 466 outlier/poor-quality samples, as described below, and were also removed prior to the PCA 467 21 analysis. The 56,435 genes that remained were used for our analyses (supplementary figure 468 5). 469
RNA-seq sample quality control 470
We excluded all samples in which less than 70% of the reads successfully mapped to the 471 genome, as reported by Kallisto, resulting in 36,761 samples. 472
Principal component analysis to identify outlier samples 473
To identify outlier samples, we conducted a principal component analysis (PCA) along the 474 following steps. First, all estimated counts were log2 transformed. Second, the data was 475 quantile normalized. Third, the covariance over the samples was calculated. Fourth, genes 476 without variance were removed from the dataset. Fifth, a PCA was conducted on the 477 covariance matrix. An arbitrary cut-off on PC 1 was selected at 0.0049 (supplementary 478 figure 6), leaving us with 32,142 samples. 479
Removal of non-Illumina samples 480
Since only a small number of samples that passed quality control (147 samples, <0.5% of 481 the total number of samples) were not sequenced on Illumina machines, we removed these 482 to avoid potential biases as a result of these different sequencing tools. This left 31,995 483 samples in our dataset. 484
Removing duplicate samples 485
A number of samples had identical values for all genes. Upon inspection, some of these 486 samples appeared to be have been used by multiple studies and uploaded to the ENA 487 database multiple times. To remove duplicate samples, we identified all samples with a 488 correlation >0.9999, randomly selected one of them to include and removed the other. 489
After this step, 31,499 samples remained. 490
Removal of technical biases 491
To identify potential technical biases in our data, we calculated the correlation between the 492 PC-scores for each PC and the following potential confounders: read length, paired/single 493 end, total reads in the dataset and percentage mapping reads (supplementary figure 7) . We 494 found that all these factors significantly correlated to our sample PC scores for multiple PCs 495 (p-value < 0.01), indicating that these technical factors would affect the co-expression 496 detected in the dataset, if not removed. We decided not to correct for GC content per gene 497 as this may also have biological meaning 49 . For a manual of the covariate removal pipeline 498 we refer to: https://github.com/molgenis/systemsgenetics/tree/master/eqtl-mapping-499 pipeline. To remove covariates, we used the "adjustcovariates" option. 500
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PCA 501
After correcting our dataset for technical biases, we conducted the following steps on the 502 matrix. First, we calculated the correlation over the genes. Second, we conducted a PCA 503 over the correlation matrix over the genes. Third, we calculated PC scores for each sample 504 for all PCs. 505
Inspection of gene PC eigencoefficients 506
To investigate if any technical biases were present for the different gene types (coding, 507 miRNA, pseudogene, etc.), we plotted the gene eigencoefficients for the first 10 PCs and 508 colored the genes by biotype (supplementary figure 8) and detected an outlier cluster on 509 PC8 and PC9, which were further investigated (supplementary figure 9) . 510
Inspection of sample PC scores 511
To better understand the origin of the outlier genes in eigenvector coefficients of PC 8 and 512
PC 9, we investigated the PC scores of the samples for these PCs. Additionally, we created a 513 plot for each of the sample PC scores of the first 10 PCs (supplementary figure 10) . We 514 observed that there is a clear biological explanation for these outliers, and therefore we 515 decided to retain these signals in the data (supplementary figure 11) . 516
Gene co-regulation analysis 517
After the quality control steps described above, we conducted a co-regulation analysis using 518 the 31,499 sample by 56,435 gene matrix. The co-regulation analysis was performed using 519 the PC eigencoefficients of the genes for each of the reliable PCs obtained from our gene-co-520 expression matrix. To determine which PCs are reliable, Cronbach's alpha 50 was calculated 521 for each PC (based on PCA of the gene-correlation matrix). Those PCs with a Cronbach's 522 Alpha ≥ 0.7 were considered reliable, and is a commonly used cutoff 51 . In total, 1,588 PCs 523 have a Cronbach's Alpha ≥ 0.7. Additionally, we calculated the variance explained by each 524 of these PCs and found the first 1588 PCs explain 66 percent of the variance 525 (supplementary figure 12) . By including signals from only these PCs, we aimed to remove 526 signals that are not reliable from our analysis. This method was previously shown to 527 perform better than using the correlation matrix directly 19 . The co-regulation scores were 528 calculated by calculating the correlation between the eigencoefficients of each gene pair. 529
Prior to this step the eigencoefficients were standard normalized per gene, after which the 530 eigencoefficients per PC were standard normalized. The logic to this step is to let the signal 531 a gene has for each PC weigh equally when determining the correlation between 2 genes. 532
Here we presumed each PC represents some biological process and those genes that are co-533 expressed in multiple processes should be reported as strongly co-expressed. This is 534 23 illustrated and further explained in 19 . The p-values of co-regulated genes can be queried via 535 the website. 536
Data visualization of sample PC scores using a t-SNE plot 537
To identify clusters for each cell type and tissue type, we used the sample PC scores, which 538 indicate how strong the signal of each sample is for each PC in the data. Here, each PC is a 539 gene expression signature for the complete set of genes. To visualize how the samples 540 cluster in a two dimensional figure, we constructed a t-SNE plot 52 based on these sample 541 PC-scores using the Rtsne library 53 (version 0.13). The t-SNE was run with a perplexity of 542 50, and we ran 10,000 iterations on our sample PC score matrix. We found that single 543 clusters were visible for many cell-and tissue-types (Figure 2a) . Most of these clusters 544 contain samples from different studies, which suggests that these clusters are not merely a 545 representation of study-specific biases. The fact that studies with multiple cell/tissue types 546
show multiple clusters further supports the suggestion that the clusters are not driven by 547 non-biological inter-study differences. 548
Gene function and HPO association predictions 549
Next, we used the PC eigenvector coefficients calculated in the previous steps to predict 550 functions for genes and to predict which phenotypes they are most likely to play a role in 551 (also described in 19 ). For each of the 1,588 reliable PCs, we determined the extent to which 552 each PC captures the activity of a biological module (defined as a group of genes annotated 553 to a term, e.g. a GO function term or HPO phenotype). 554
To do this, the following steps were taken. First, for each PC, a student's T-test was 555 conducted between the eigencoefficients of the genes annotated to a particular term and a 556 group of genes serving as a background. This background consisted of all genes annotated 557 to any term in a specific database, except for those annotated to the term for which the T-558 test was conducted. Genes that were not annotated to any term in a database were 559 excluded from this background, as these genes have not yet been annotated to any 560 biological functions/terms (because they have not been studied yet). Second, the resulting 561 p-values were transformed into a z-score, which are indicating to which extend each PC 562 represents a biological function/term. This was repeated for each of the 1,588 significant 563 PCs, resulting in a z-score for each PC-term combination. Higher absolute z-values between 564 a term and a PC indicate that the signal for that PC is more strongly related to that term. 565
We applied this methodology to the gene sets described by terms in the following 566 databases: Reactome and KEGG pathways, Gene Ontology (GO) molecular function, GO 567 biological process and GO cellular component terms and finally to HPO terms. We excluded 568 24 terms for which fewer than 10 genes are annotated because predictions for smaller groups 569 of genes are less accurate and might be misleading. Predictions were made for 8,657 gene 570 sets in total. For each term, we calculated how well each PC captured the signal of the 571 genes that are annotated to that term. Third and last, to predict which genes are correlated 572 to a particular HPO term, we correlated the 1,588 z-scores for that term (as calculated 573 above) with the 1,588 eigenvector coefficients of a gene. These correlations were 574 transformed into z-scores, which we refer to as prioritization scores. This can be done for 575 any gene-to-HPO term combination. However, when a gene is already explicitly annotated 576
to the term and we wish to predict whether that gene is predicted to be involved in that 577 term, there is a small circular bias as the z-scores for this term were partly calculated based 578 on this gene. To remove this bias in these circumstances, the 1,588 z-scores for a gene set 579 were first re-calculated while assuming these gene is not involved in that term, after which 580 the prediction for this gene was made. 581
Validation of the GO, HPO and Reactome term predictions 582
To determine the accuracy of our GO, HPO and Reactome term predictions, we calculated 583 how well we could predict genes that are part of a term. To do so, we used the prioritization 584 z-scores that the genes had for a particular term. For each term, we calculated an Area 585
Under the Curve (AUC), using a Mann-Whitney U test, on the prioritization scores of the 586 genes that are part of the term versus those that are not part of the term. These AUCs 587 indicate how accurate the predictions were, with an AUC of 1 indicating perfect predictions 588 and an AUC of 0.5 indicating no predictive power. The average AUC for each category was 589 calculated based on all terms with at least 10 genes annotated and for which the p-value 590 was less than 0.05 (Bonferroni corrected for the number of pathways for the category 591 tested) (Figure 2b) . 592
GADO predictions 593
To identify potential causative variants in patients, we used HPO term annotations 594 describing the patient's features. The gene prediction z-scores for an HPO term were used 595 to rank the genes. If a patient's phenotype was described by more than one HPO term, a 596 meta-analysis was conducted. In this case a weighted z-score was calculated by adding the 597 HPO z-scores for all the patient's HPO terms and then dividing by the square root of the 598 number of HPO terms. In this calculation, we used only those HPO terms, which have 599 significant predictive power (based on whether genes annotated to this term have 600 significantly absolute higher z-scores than those not annotated to the term as calculated in 601 the section "Gene function and HPO association predictions"). If the predictions for a 602 patient's HPO term were not significant, the parent/umbrella HPO term(s) was used. (The  603   25 online GADO tool supplies the user with a list of parent terms from which the user can then 604 manually select which terms should be used in the analysis (supplementary figure 1) ). If 605 this parent term also did not have significant predictive power, the parent's parent term was 606 used (thus moving up the HPO tree until a parent term is found which has significant 607 predictive power). If an HPO term has multiple parents, predictions were made using each 608 parent and the results are reported separately. The genes with the highest z-scores are 609 most relevant for the patient according to GADO's predictions. This analysis can be 610 conducted at: https://www.genenetwork.nl/gado. 611
Validation of disease-gene predictions 612
To benchmark our method we used the OMIM morbid map 5 downloaded on March 26, 613 2018, containing all disease-gene-phenotype entries. From this list, we extracted the 614 disease-gene associations, excluding non-disease and susceptibility entries. We extracted 615 the provisional disease-gene associations separately. For each disease in OMIM, we used 616 GADO to determine the rank of the causative gene among all genes in the OMIM morbid 617 map. For this we used all phenotypes annotated to the OMIM disease. If any of the HPO 618 terms did not have significant predictive power, the parent term(s) was used. 619
To determine if these distributions were significantly different from what we expect by 620 chance, we permuted the data. We replaced the existing gene-OMIM annotation but 621 assigned every gene to a new disease (keeping the phenotypic features for a disease 622 together), assuring that the randomly selected gene was not already annotated to any of 623 the phenotypes of the original gene. 624
Cohort of previously solved cases 625
To test if GADO could help prioritize genes that contain the causative variant, we used 83 626 samples of patients who were previously genetically diagnosed through whole exome 627 analysis or gene panel analysis. These samples encompass a wide variety of different 628
Mendelian disorders (supplementary table 2). To assess which genes harbor potentially 629 causative variants, we first called and annotated the variants from the exome sequencing 630 files. 631
Variant calling 632
We used the available WES or WGS data from patients with and without genetic diagnosis. 633
These samples were genotyped using a relatively standard BWA and GATK pipeline. For a 634 detailed description of the genotype pipeline see: https://molgenis.gitbooks.io/ngs_dna/ 635 (version 3.4.0). For the WGS samples, we confined our analysis to the exome. 636
